NASDAQ:RVPH Reviva Pharmaceuticals Q4 2024 Earnings Report $0.48 0.00 (-0.93%) As of 03:59 PM Eastern ProfileEarnings HistoryForecast Reviva Pharmaceuticals EPS ResultsActual EPS-$3.00Consensus EPS -$4.40Beat/MissBeat by +$1.40One Year Ago EPSN/AReviva Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AReviva Pharmaceuticals Announcement DetailsQuarterQ4 2024Date3/31/2025TimeAfter Market ClosesConference Call DateMonday, March 31, 2025Conference Call Time8:00AM ETUpcoming EarningsReviva Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Reviva Pharmaceuticals Earnings HeadlinesZacks Research Has Optimistic Outlook of RVPH Q3 EarningsAugust 22 at 1:28 AM | americanbankingnews.comRVPH: Patent Filed for New FormulationAugust 17, 2026 | finance.yahoo.comSEPT 25th — Become 1 of 1,806,000 New “Musk Millionaires”James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altucher is hosting a free masterclass revealing what he says is locked inside a sealed briefcase detailing Musk's plans. Attendees who join early can also access a $1,000 bonus offer included with the presentation.August 24 at 1:00 AM | Paradigm Press (Ad)Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 13, 2026 | finanznachrichten.deReviva Pharmaceuticals Files U.S. Patent Application for New Brilaroxazine Formulation, Expects FDA Feedback in Q4 2026 August 12, 2026 | quiverquant.comQReviva Reports Second Quarter 2026 Financial Results and Recent Business HighlightsAugust 12, 2026 | globenewswire.comSee More Reviva Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email. Email Address About Reviva PharmaceuticalsReviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes. The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry. Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs. Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.View Reviva Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It MattersMongoDB Is Surging—And the Next Catalyst Is Almost Here5 of the Most-Upgraded Stocks Over the Last Quarter Are All Software Names—Here's WhyMarketBeat Week in Review – 08/17 - 08/21BJ’s Wholesale Club Is Turning Stronger Fundamentals Into a Bullish SetupFlash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to Watch$27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over Upcoming Earnings Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026)Toronto Dominion Bank (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
